van la Parra RFD - Search Results

1

Incidence and Outcome of Breast Biopsy Procedures During Follow-up After Treatment for Breast Cancer.

van la Parra RFD, Liao K, Smith BD, Yang WT, Leung JWT, Giordano SH, Kuerer HM. van la Parra RFD, et al. JAMA Surg. 2018 Jun 1;153(6):559-568. doi: 10.1001/jamasurg.2017.5572. JAMA Surg. 2018. PMID: 29387884 Free PMC article.

2

Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials.

van la Parra RF, Kuerer HM. van la Parra RF, et al. Breast Cancer Res. 2016 Mar 8;18(1):28. doi: 10.1186/s13058-016-0684-6. Breast Cancer Res. 2016. PMID: 26951131 Free PMC article. Review.

3

Breast Cancer Clinical Trials: Past Half Century Moving Forward Advancing Patient Outcomes.

Kuerer HM, van la Parra RF. Kuerer HM, et al. Ann Surg Oncol. 2016 Oct;23(10):3145-52. doi: 10.1245/s10434-016-5326-9. Epub 2016 Jun 30. Ann Surg Oncol. 2016. PMID: 27364503 Review.

4

Multimodality Imaging for Evaluating Response to Neoadjuvant Chemotherapy in Breast Cancer.

Rauch GM, Adrada BE, Kuerer HM, van la Parra RF, Leung JW, Yang WT. Rauch GM, et al. AJR Am J Roentgenol. 2017 Feb;208(2):290-299. doi: 10.2214/AJR.16.17223. Epub 2016 Nov 3. AJR Am J Roentgenol. 2017. PMID: 27809573 Review.

5

Long-term Results After Oncoplastic Surgery for Breast Cancer: A 10-year Follow-up.

Clough KB, van la Parra RFD, Thygesen HH, Levy E, Russ E, Halabi NM, Sarfati I, Nos C. Clough KB, et al. Among authors: van la parra rfd. Ann Surg. 2018 Jul;268(1):165-171. doi: 10.1097/SLA.0000000000002255. Ann Surg. 2018. PMID: 28448389 Clinical Trial.

6

Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.

van la Parra RFD, Tadros AB, Checka CM, Rauch GM, Lucci A Jr, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM. van la Parra RFD, et al. Br J Surg. 2018 Apr;105(5):535-543. doi: 10.1002/bjs.10755. Epub 2018 Feb 21. Br J Surg. 2018. PMID: 29465744 Free PMC article.

7

Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy.

Sun S, van la Parra RFD, Rauch GM, Checka C, Tadros AB, Lucci A Jr, Teshome M, Black D, Hwang RF, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM. Sun S, et al. Among authors: van la parra rfd. Ann Surg Oncol. 2019 Oct;26(10):3071-3079. doi: 10.1245/s10434-019-07533-2. Epub 2019 Jul 24. Ann Surg Oncol. 2019. PMID: 31342361

8

Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.

Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM; Exceptional Responders Clinical Trials Group. Kuerer HM, et al. Lancet Oncol. 2022 Dec;23(12):1517-1524. doi: 10.1016/S1470-2045(22)00613-1. Epub 2022 Oct 25. Lancet Oncol. 2022. PMID: 36306810 Clinical Trial.

9

A simple risk score to predict the presence of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node.

van la Parra RF, Peer PG, de Roos WK, Ernst MF, de Wilt JH, Bosscha K. van la Parra RF, et al. World J Surg. 2014 May;38(5):1070-6. doi: 10.1007/s00268-013-2387-9. World J Surg. 2014. PMID: 24305938

10

Is SLN Biopsy Alone Safe in SLN Positive Breast Cancer Patients?

van la Parra RF, de Wilt JH, Mol SJ, Mulder AH, de Roos WK, Bosscha K. van la Parra RF, et al. Breast J. 2015 Nov-Dec;21(6):621-6. doi: 10.1111/tbj.12496. Epub 2015 Sep 22. Breast J. 2015. PMID: 26391102

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters